Somatic hypermutation (SHM) is the body’s natural process for generating potent antibodies to fight disease.
AnaptysBio’s SHM-XEL platform combines SHM with mammalian cell expression, secretion and display, deep sequencing, and flow cytometry to produce antibodies for therapeutic applications.
This platform is being employed for both discovery of new antibodies and optimisation of existing antibodies to generate product candidates for the company’s internal pipeline and partners.
E-WorkBook provides AnaptysBio with searchable, scalable and secure information management that is applicable across the business, improving internal and external collaboration, process efficiency and data consistency.
E-WorkBook enables AnaptysBio to secure unparalleled context with the data, to search, annotate and report swiftly on the results and to meet their scientific goals.
AnaptysBio Chairman and CEO Tom Smart said research productivity is a priority for industry, including the ability to timely and comprehensively collect, retrieve and analyze data.
"We look forward to utilising E-WorkBook to provide us with greater visibility and control of data generated using our SHM-XEL platform, and enhance our ability to search, retrieve and generate reports for scientific analysis," Smart said.